New study tests safer blood thinners for Clot-Prone patients
NCT ID NCT07372170
First seen Jan 31, 2026
Summary
This study looks at two types of blood thinners—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—to see which works better at preventing repeat blood clots in people with a low-risk form of antiphospholipid syndrome (APS). APS is an autoimmune condition that raises the risk of dangerous clots. Researchers will follow 600 adults already taking one of these medications in routine care, tracking clot recurrences and bleeding events. The goal is to provide real-world evidence on whether newer DOACs are a safe option for these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Universitario Infanta Leonor
RECRUITINGMadrid, Madrid, 28031, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario Infanta Sofía
RECRUITINGMadrid, Madrid, Spain
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)
What this could lead to
If successful, this study could clarify whether DOACs are a safe and effective alternative to standard blood thinners for preventing repeat clots in low-risk antiphospholipid syndrome patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It cannot prove cause and effect, and findings may not apply to higher-risk patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.